RXST (RxSight, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RXST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Eric Weinberg | See remarks | M | — | — |
| 2026-09-09 | Ronald M MD Kurtz | Chief Medical Officer | MIXED | — | — |
| 2026-09-09 | Mark Wilterding | Chief Financial Officer | MIXED | — | — |
| 2026-09-09 | Ilya Goldshleger | Chief Operating Officer | MIXED | — | — |
| 2026-09-09 | Eric Weinberg | See remarks | MIXED | — | — |
| 2026-09-02 | Mark Wilterding | Chief Financial Officer | MIXED | — | — |
| 2026-09-02 | Ronald M MD Kurtz | Chief Medical Officer | MIXED | — | — |
| 2026-09-02 | Ilya Goldshleger | Chief Operating Officer | MIXED | — | — |
| 2026-09-02 | Eric Weinberg | See remarks | MIXED | — | — |
| 2026-07-24 | Aziz Mottiwala | President and CEO | A | — | — |
| 2026-06-18 | Robert Keith Warner | Director | A | — | — |
| 2026-06-18 | Tamara Fountain | Director | A | — | — |
| 2026-06-18 | WILLIAM J PHD LINK | Director | A | — | — |
| 2026-06-18 | ROBERT J PALMISANO | Director | A | — | — |
| 2026-06-18 | Bakker Juliet Tammenoms | Director | A | — | — |
| 2026-06-18 | Julie Andrews | Director | A | — | — |
| 2026-06-18 | RAYMOND W COHEN | Director | A | — | — |
| 2026-06-18 | Shweta Maniar | Director | A | — | — |
| 2026-06-18 | Jesse Anderson Corley | Director | A | — | — |
| 2026-04-20 | Ilya Goldshleger | Chief Operating Officer | M | — | — |
| 2026-03-03 | Ilya Goldshleger | Chief Operating Officer | A | — | — |
| 2026-03-03 | Eric Weinberg | See remarks | A | — | — |
| 2026-03-03 | Ronald M MD Kurtz | President & CEO | A | — | — |
| 2026-03-03 | Scott Gaines | Chief Customer Officer | MIXED | — | — |
| 2026-03-03 | Mark Wilterding | Chief Financial Officer | MIXED | — | — |
| 2026-01-30 | Mark Wilterding | Chief Financial Officer | A | — | — |
| 2025-09-26 | Ilya Goldshleger | See remarks | M | — | — |
| 2025-08-04 | RAYMOND W COHEN | Director | A | — | — |
| 2025-06-04 | Shweta Maniar | Director | A | — | — |
| 2025-06-04 | Tamara Fountain | Director | A | — | — |
| 2025-06-04 | Julie Andrews | Director | A | — | — |
| 2025-06-04 | Bakker Juliet Tammenoms | Director | A | — | — |
| 2025-06-04 | Robert Keith Warner | Director | A | — | — |
| 2025-06-04 | Jesse Anderson Corley | Director | A | — | — |
| 2025-06-04 | ROBERT J PALMISANO | Director | A | — | — |
| 2025-06-04 | WILLIAM J PHD LINK | Director | A | — | — |
| 2025-06-03 | Eric Weinberg | See remarks | M | — | — |
| 2025-04-15 | Shelley B Thunen | See remarks | M | — | — |
| 2025-03-13 | Tamara Fountain | Director | Sell | — | — |
| 2025-02-27 | Eric Weinberg | See remarks | A | — | — |
| 2025-02-27 | Ronald M MD Kurtz | President & CEO | A | — | — |
| 2025-02-27 | Shelley B Thunen | See remarks | A | — | — |
| 2025-02-27 | Ilya Goldshleger | See remarks | A | — | — |
| 2025-01-27 | Shweta Maniar | Director | Sell | — | — |
| 2025-01-17 | Jesse Anderson Corley | Director | Buy | — | — |
| 2024-12-03 | Ilya Goldshleger | See remarks | MIXED | — | — |
| 2024-11-26 | Shweta Maniar | Director | Sell | — | — |
| 2024-11-26 | Ilya Goldshleger | See remarks | MIXED | — | — |
| 2024-11-18 | Ilya Goldshleger | See remarks | MIXED | — | — |
| 2024-11-14 | Ilya Goldshleger | See remarks | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,016,778 | — |
| — | Director | 1,840,244 | — |
| — | Director | 1,385,037 | — |
| — | Chief Medical Officer | 836,385 | — |
| — | See remarks | 535,494 | — |
| — | Director | 407,647 | — |
| — | Director | 96,140 | — |
| — | Director | 93,310 | — |
| — | Director | 86,731 | — |
| — | Director | 85,296 | — |
| — | Chief Operating Officer | 82,881 | — |
| — | Director | 78,076 | — |
| — | Director | 78,076 | — |
| — | Director | 72,582 | — |
| — | Director | 66,532 | — |
| — | Director | 55,172 | — |
| — | See remarks | 38,354 | — |
| — | Chief Financial Officer | 32,814 | — |
| — | Chief Customer Officer | 14,848 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RXST quote page; the site-wide leaderboard is on the insider transactions hub.